Skip to content

Efficacy and Safety of Cilostazol Versus Aspirin for Secondary Prevention in Patients With Ischemic Stroke and Cerebral Microbleeds: A Real-World Cohort Study Using Propensity Score Matching

Efficacy and Safety of Cilostazol Versus Aspirin for Secondary Prevention in Patients With Ischemic Stroke and Cerebral Microbleeds: A Real-World Cohort Study Using Propensity Score Matching

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119026
Enrollment
Unknown
Registered
2026-02-14
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

Aspirin group:N/A
Cilostazol group:N/A

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Hospitalized within 6 months of onset, with ischemic stroke confirmed by Magnetic Resonance Imaging (MRI), and the stroke etiology clearly defined as non-cardioembolic according to the TOAST classification; 3. Currently receiving monotherapy antiplatelet treatment (either Aspirin or Cilostazol) at the time of enrollment; 4. Underwent Susceptibility-Weighted Imaging (SWI) during hospitalization, and the presence of at least one Cerebral Microbleed (CMB) was confirmed.

Exclusion criteria

Exclusion criteria: 1. Stroke etiology is cardioembolic; 2. Patients who continuously received dual antiplatelet therapy, any form of anticoagulation therapy, or no antiplatelet medication at all within 6 months prior to enrollment; 3. History of severe adverse reactions to Aspirin or Cilostazol (such as active bleeding, severe allergy, etc.), leading to inability to comply with the medication regimen; 4. Patients with severe comorbidities, specifically including: severe hepatic insufficiency (defined as Child-Pugh Class B or C), renal failure (defined as estimated Glomerular Filtration Rate (eGFR)<30ml/min/1.73m2),evere heart failure [NYHA Class III-IV], or history of active malignant tumor; 5. Patients with a definite or probable diagnosis of Cerebral Amyloid Angiopathy (CAA) based on the Boston 2.0diagnostic criteria; 6. Severe missing key baseline or follow-up data that prevents effective evaluation.

Design outcomes

Primary

MeasureTime frame
any stroke;intracranial hemorrhage during follow-up;

Secondary

MeasureTime frame
ischemic stroke;non-bleeding adverse events;myocardial infarction;all-cause death;other bleeding events;composite endpoint of major adverse cardiovascular and cerebrovascular events;vascular death;

Countries

China

Contacts

Public ContactSheng Zhang

Zhejiang Provincial People's Hospital

zhangsheng@hmc.edu.cn+86 18758188313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026